Pfizer and BioNTech announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
14 Sep 2020
07 Sep 2020
Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following:
02 Sep 2020
Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19.
01 Sep 2020
Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe Covid-19.
13 Aug 2020
Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients.
08 Jul 2020
Ridgeback Biotherapeutics has commenced enrolment for the phase 2 trial of its Covid-19 drug candidate EIDD-2801, an orally-bioavailable form of a potent ribonucleoside analog.
26 Jun 2020
Theravance Biopharma has dosed the first patient in the phase 2 study of lung-selective and nebulized Janus kinase inhibitor (JAKi) TD-0903 to treat hospitalised patients with acute lung injury (ALI) due to Covid-19.
11 Jun 2020
Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO (nivolumab), as front-line maintenance treatment of newly-diagnosed advanced ovarian cancer.
13 Mar 2020
Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection (CDI).
18 Oct 2019
Trial to evaluate the effectiveness of KRYSTEXXA to sustain reduced serum uric acid levels for post-kidney transplant adults; a vulnerable population.